Single rapamycin administration induces prolonged downward shift in defended body weight in rats

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Hebert, Mark ^a   Licursi, Maria ^a   Jensen, Brittany ^a   Baker, Ashley ^a   Milway, Steve ^a   Malsbury, Charles ^a   Grant, Virginia L ^a   Adamec, Robert ^a   Hirasawa, Michiru ^a   Blundell, Jacqueline ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DESENSITIZATION; ENERGY BALANCE; FAT MASS; FOOD INTAKE; GLUCOSE INTOLERANCE; MALAISE; MALE; NONHUMAN; OVERNUTRITION; RAT; WEIGHT GAIN; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; BODY WEIGHT; BRAIN; DRUG EFFECTS; DRUG POTENTIATION; EATING; ENERGY METABOLISM; HOMEOSTASIS; INJECTION; METABOLISM; SPRAGUE DAWLEY RAT; TIME;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; BRAIN; DRUG SYNERGISM; EATING; ENERGY METABOLISM; HOMEOSTASIS; INJECTIONS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84900445816     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093691     Document Type: Article

References (25)

1. Bray GA, Tartaglia LA (2000) Medicinal strategies in the treatment of obesity. Nature 404: 672-677. (Pubitemid 30205072)
2. Leibel RL, Rosenbaum M, Hirsch J (1995) Changes in energy expenditure resulting from altered body weight. N Engl J Med 332: 621-628.
3. Wadden TA, Sternberg JA, Letizia KA, Stunkard AJ, Foster GD (1989) Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 13 Suppl 2: 39-46. (Pubitemid 20149399)
4. Ryan KK, Woods SC, Seeley RJ (2012) Central nervous system mechanisms linking the consumption of palatable high-fat diets to the defense of greater adiposity. Cell Metab 15: 137-149.
5. Zhou H, Huang S The complexes of mammalian target of rapamycin. Curr Protein Pept Sci 11: 409-424.
6. Fang Y, Westbrook R, Hill C, Boparai RK, Arum O, et al. (2013) Duration of rapamycin treatment has differential effects on metabolism in mice. Cell Metab 17: 456-462.
7. Deblon N, Bourgoin L, Veyrat-Durebex C, Peyrou M, Vinciguerra M, et al. (2012) Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol 165: 2325-2340.
8. Chang GR, Chiu YS, Wu YY, Chen WY, Liao JW, et al. (2009) Rapamycin protects against high fat diet-induced obesity in C57BL/6J mice. J Pharmacol Sci 109: 496-503.
9. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G, et al. (2006) Hypothalamic mTOR signaling regulates food intake. Science 312: 927-930. (Pubitemid 43727328)
10. Yang SB, Tien AC, Boddupalli G, Xu AW, Jan YN, et al. (2012) Rapamycin ameliorates age-dependent obesity associated with increased mTOR signaling in hypothalamic POMC neurons. Neuron 75: 425-436.
11. Martins L, Fernandez-Mallo D, Novelle MG, Vazquez MJ, Tena-Sempere M, et al. (2012) Hypothalamic mTOR signaling mediates the orexigenic action of ghrelin. PLoS One 7: e46923.
12. Blundell J, Kouser M, Powell CM (2008) Systemic inhibition of mammalian target of rapamycin inhibits fear memory reconsolidation. Neurobiol Learn Mem 90: 28-35.
13. Fifield K, Hebert M, Angel R, Adamec R, Blundell J (2013) Inhibition of mTOR kinase via rapamycin blocks persistent predator stress-induced hyperarousal. Behav Brain Res 256: 457-463.
14. Huang S, Houghton PJ (2001) Resistance to rapamycin: a novel anticancer drug. Cancer Metastasis Rev 20: 69-78. (Pubitemid 34074681)
15. Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, et al. (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57: 945-957.
16. Houde VP, Brule S, Festuccia WT, Blanchard PG, Bellmann K, et al. (2010) Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes 59: 1338-1348.
17. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, et al. (2012) Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science 335: 1638-1643.
18. Yanez JA, Forrest ML, Ohgami Y, Kwon GS, Davies NM (2008) Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin. Cancer Chemother Pharmacol 61: 133-144. (Pubitemid 47512635)
19. Erlich S, Alexandrovich A, Shohami E, Pinkas-Kramarski R (2007) Rapamycin is a neuroprotective treatment for traumatic brain injury. Neurobiol Dis 26: 86-93. (Pubitemid 46436489)
20. Wang CY, Kim HH, Hiroi Y, Sawada N, Salomone S, et al. (2009) Obesity increases vascular senescence and susceptibility to ischemic injury through chronic activation of Akt and mTOR. Sci Signal 2: ra11.
21. Yatscoff RW, Wang P, Chan K, Hicks D, Zimmerman J (1995) Rapamycin: distribution, pharmacokinetics, and therapeutic range investigations. Ther Drug Monit 17: 666-671.
22. Hoeffer CA, Klann E (2010) mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci 33: 67-75.
23. Blouet C, Schwartz GJ (2012) Brainstem nutrient sensing in the nucleus of the solitary tract inhibits feeding. Cell Metab 16: 579-587.
24. Varela L, Martinez-Sanchez N, Gallego R, Vazquez MJ, Roa J, et al. (2012) Hypothalamic mTOR pathway mediates thyroid hormone-induced hyperphagia in hyperthyroidism. J Pathol 227: 209-222.
25. Zhang W, Zhang C, Fritze D, Chai B, Li J, et al. (2013) Modulation of food intake by mTOR signalling in the dorsal motor nucleus of the vagus in male rats: focus on ghrelin and nesfatin-1. Exp Physiol 98: 1696-1704.